Trade Report: The Gargoyle Investment Advisor L.L.C. decides to keep it stake in Allscripts Healthcare Solutions Inc. (MDRX) to the level of $245,000

The Gargoyle Investment Advisor L.L.C. decides to keep it stake in Allscripts Healthcare Solutions Inc. (MDRX) to the level of $245,000

Gargoyle Investment Advisor L.L.C. lowered its position in shares of Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) by 79.0% during the second quarter, Holdings Channel reports. The institutional investor owned 19,310 shares of the company’s stock after selling 72,612 shares during the period. Gargoyle Investment Advisor L.L.C.’s holdings in Allscripts Healthcare Solutions were worth $245,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Boston Advisors LLC boosted its stake in shares of Allscripts Healthcare Solutions by 0.5% in the second quarter. Boston Advisors LLC now owns 50,367 shares of the company’s stock worth $640,000 after buying an additional 250 shares in the last quarter. Capstone Asset Management Co. boosted its stake in shares of Allscripts Healthcare Solutions by 3.1% in the second quarter. Capstone Asset Management Co. now owns 16,387 shares of the company’s stock worth $208,000 after buying an additional 500 shares in the last quarter. IBM Retirement Fund boosted its stake in shares of Allscripts Healthcare Solutions by 3.9% in the second quarter. IBM Retirement Fund now owns 18,847 shares of the company’s stock worth $239,000 after buying an additional 708 shares in the last quarter. Springbok Capital Management LLC boosted its stake in shares of Allscripts Healthcare Solutions by 13.4% in the first quarter. Springbok Capital Management LLC now owns 11,800 shares of the company’s stock worth $156,000 after buying an additional 1,397 shares in the last quarter. Finally, Teachers Advisors Inc. boosted its stake in shares of Allscripts Healthcare Solutions by 2.2% in the first quarter. Teachers Advisors Inc. now owns 146,355 shares of the company’s stock worth $1,933,000 after buying an additional 3,168 shares in the last quarter.

Shares of Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) traded up 0.69% during trading on Friday, hitting $13.09. 1,856,682 shares of the company were exchanged. The firm has a market capitalization of $2.44 billion, a PE ratio of 818.12 and a beta of 1.21. The firm’s 50-day moving average price is $12.96 and its 200 day moving average price is $13.27. Allscripts Healthcare Solutions Inc. has a 12 month low of $11.47 and a 12 month high of $15.78.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its earnings results on Thursday, August 4th. The company reported $0.14 EPS for the quarter, hitting analysts’ consensus estimates of $0.14. The company earned $386.50 million during the quarter, compared to analysts’ expectations of $403.13 million. Allscripts Healthcare Solutions had a net margin of 0.20% and a return on equity of 5.34%. Allscripts Healthcare Solutions’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the business earned $0.12 EPS. On average, equities research analysts expect that Allscripts Healthcare Solutions Inc. will post $0.59 earnings per share for the current fiscal year.

A number of brokerages have commented on MDRX. Robert W. Baird reaffirmed a “buy” rating on shares of Allscripts Healthcare Solutions in a report on Saturday, July 9th. Zacks Investment Research cut shares of Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, August 10th. Piper Jaffray Cos. reaffirmed a “neutral” rating and set a $15.00 target price (up from $12.00) on shares of Allscripts Healthcare Solutions in a report on Monday, August 8th. Jefferies Group reaffirmed a “buy” rating on shares of Allscripts Healthcare Solutions in a report on Tuesday, July 5th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $19.00 target price on shares of Allscripts Healthcare Solutions in a report on Sunday, August 7th. Eleven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Allscripts Healthcare Solutions has a consensus rating of “Buy” and a consensus target price of $16.19.

In related news, SVP Dennis Olis sold 7,000 shares of Allscripts Healthcare Solutions stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $14.00, for a total value of $98,000.00. Following the completion of the sale, the senior vice president now directly owns 210,887 shares in the company, valued at approximately $2,952,418. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Black sold 15,000 shares of Allscripts Healthcare Solutions stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the sale, the chief executive officer now owns 1,177,009 shares of the company’s stock, valued at $15,301,117. The disclosure for this sale can be found here. 0.75% of the stock is currently owned by corporate insiders.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc delivers information technology (IT) and services to help healthcare organizations in clinical, financial and operational results. The Company operates through two segments: Clinical and Financial Solutions, and Population Health. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record (EHR)-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services.

Related posts

Leave a Comment